{
    "info": {
        "nct_id": "NCT03506373",
        "official_title": "Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia",
        "inclusion_criteria": "* Histological confirmation of WM; patients may have newly diagnosed, relapsed, or refractory disease; (definition: newly diagnosed; patients previously untreated for WM, relapse; patients who have received prior treatment for WM and now have disease recurrence; refractory; patients who have received anti-WM therapy and are noted to have progressive disease while on therapy, or those patients who demonstrated disease progression within 6 months of the last anti-WM treatment); NOTE: Ibrutinib naïve patients are allowed; if previously treated with ibrutinib, subject must have reached a response of at least stable disease (SD) and cannot have progressed while on ibrutinib; if subject stopped taking ibrutinib for reasons other than progression, they cannot have progressed for at least 6 months post last dose of ibrutinib\n* Presence of measurable disease as defined by: presence of immunoglobulin M (IgM) paraprotein, measurable lymphadenopathy on imaging studies and/or physical exam, and/or bone marrow infiltration > 10%\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2\n* Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)\n* Platelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration) (NOTE: platelet transfusions in order to help patients meet eligibility criteria are not allowed)\n* Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome, in which case the direct bilirubin must be =< 1.5 x ULN (obtained =< 14 days prior to registration)\n* Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (obtained =< 14 days prior to registration)\n* Calculated creatinine clearance must be >= 30 ml/min using the Cockcroft Gault formula (obtained =< 14 days prior to registration)\n* Negative pregnancy test done at screening and =< 3 days (72 hours) prior to registration, for women of childbearing potential\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens and bone marrow specimens for correlative research\n* Willingness to return to enrolling institution for follow-up\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Failure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior treatment for WM\n* Major surgical procedure (including open biopsy, excluding central line intravenous (IV) and port-a-cath placement) within =< 14 days prior to initiating study treatment, or anticipation of the need for major surgery during the course of the study treatment\n* Radiotherapy =< 14 days prior to registration; if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib\n* Systemic treatment, =< 14 days before registration, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or St. John's wort\n* Systemic anti-cancer therapy or participation in other clinical trials, including those with other investigational agents not included in this trial, =< 28 days of registration and throughout the duration of active treatment in this trial\n* Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not; prior bortezomib treatment is allowed as per: patients with prior exposure to bortezomib will be allowed if they do not have disease refractory to bortezomib)\n* Central nervous system involvement (Bing-Neel syndrome)\n* Infection requiring systemic antibiotic therapy or other serious infection =< 7 days prior to registration\n* Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, serious cardiac arrhythmia requiring medication (other than adequately rate-controlled atrial fibrillation), symptomatic congestive heart failure, unstable angina, stroke/transient ischemic attack (TIA) within the past 6 months or myocardial infarction within the past 6 months\n* Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent\n* Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ibrutinib, including difficulty swallowing\n* History of any other prior malignancy; (NOTE: Exception to this are adequately treated non-melanoma skin cancers, any in situ cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least two years prior to study enrollment)\n* Patient has >= grade 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination during the screening period\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of child bearing potential (WCBP) who are unwilling to employ effective contraception; effective contraception would be defined as utilizing 2 simultaneous methods of contraception from the time of signing consent through 90 days after the last dose of the study drugs unless they agree to participate in true abstinence when this is in line with the preferred and usual lifestyle of the subject; (WCBP: A female who is sexually mature and who: [1] has not undergone a hysterectomy or bilateral oophorectomy; or [2] has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time in the preceding 24 consecutive months])\n* Evidence of any other serious medical condition (such as psychiatric illness, infectious diseases, physical or laboratory findings) that may interfere with the planned treatment, affect compliance or place the patient at high risk from treatment-related complications or potentially interfere with the completion of the treatment as per the protocol\n* Ongoing, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive\n* Liver disease with Child-Pugh class B or C liver dysfunction\n* Current treatment with a combination of ibrutinib and strong CYP3A inhibitors",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histological confirmation of WM; patients may have newly diagnosed, relapsed, or refractory disease; (definition: newly diagnosed; patients previously untreated for WM, relapse; patients who have received prior treatment for WM and now have disease recurrence; refractory; patients who have received anti-WM therapy and are noted to have progressive disease while on therapy, or those patients who demonstrated disease progression within 6 months of the last anti-WM treatment); NOTE: Ibrutinib naïve patients are allowed; if previously treated with ibrutinib, subject must have reached a response of at least stable disease (SD) and cannot have progressed while on ibrutinib; if subject stopped taking ibrutinib for reasons other than progression, they cannot have progressed for at least 6 months post last dose of ibrutinib",
            "criterions": [
                {
                    "exact_snippets": "Histological confirmation of WM",
                    "criterion": "Waldenström macroglobulinemia (WM) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients may have newly diagnosed, relapsed, or refractory disease",
                    "criterion": "WM disease status",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "newly diagnosed",
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Ibrutinib naïve patients are allowed",
                    "criterion": "ibrutinib treatment history",
                    "requirements": [
                        {
                            "requirement_type": "ibrutinib naïve",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if previously treated with ibrutinib, subject must have reached a response of at least stable disease (SD) and cannot have progressed while on ibrutinib",
                    "criterion": "response to prior ibrutinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "minimum response",
                            "expected_value": "stable disease"
                        },
                        {
                            "requirement_type": "progression on ibrutinib",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "if subject stopped taking ibrutinib for reasons other than progression, they cannot have progressed for at least 6 months post last dose of ibrutinib",
                    "criterion": "disease progression after stopping ibrutinib (for reasons other than progression)",
                    "requirements": [
                        {
                            "requirement_type": "progression within 6 months post last dose",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to return to enrolling institution for follow-up",
            "criterions": [
                {
                    "exact_snippets": "Willingness to return to enrolling institution for follow-up",
                    "criterion": "willingness to return for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to provide mandatory blood specimens and bone marrow specimens for correlative research",
            "criterions": [
                {
                    "exact_snippets": "Willingness to provide mandatory blood specimens",
                    "criterion": "blood specimen provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness to provide mandatory ... bone marrow specimens",
                    "criterion": "bone marrow specimen provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "hemoglobin measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "ANC laboratory value timing",
                    "requirements": [
                        {
                            "requirement_type": "time from registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of measurable disease as defined by: presence of immunoglobulin M (IgM) paraprotein, measurable lymphadenopathy on imaging studies and/or physical exam, and/or bone marrow infiltration > 10%",
            "criterions": [
                {
                    "exact_snippets": "presence of immunoglobulin M (IgM) paraprotein",
                    "criterion": "immunoglobulin M (IgM) paraprotein",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable lymphadenopathy on imaging studies and/or physical exam",
                    "criterion": "lymphadenopathy",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bone marrow infiltration > 10%",
                    "criterion": "bone marrow infiltration",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance must be >= 30 ml/min using the Cockcroft Gault formula (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance must be >= 30 ml/min using the Cockcroft Gault formula",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft Gault formula"
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "creatinine clearance measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration) (NOTE: platelet transfusions in order to help patients meet eligibility criteria are not allowed)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 75,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet transfusions in order to help patients meet eligibility criteria are not allowed",
                    "criterion": "platelet transfusions to meet eligibility",
                    "requirements": [
                        {
                            "requirement_type": "use for eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate transaminase (AST) ... =< 3 x ULN (obtained =< 14 days prior to registration)",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained =< 14 days prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 3 x ULN (obtained =< 14 days prior to registration)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained =< 14 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome, in which case the direct bilirubin must be =< 1.5 x ULN (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless due to Gilbert's syndrome, in which case the direct bilirubin must be =< 1.5 x ULN",
                    "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "timing of bilirubin measurement",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test done at screening and =< 3 days (72 hours) prior to registration, for women of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test done at screening ... for women of childbearing potential",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 72,
                                        "unit": "hours"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for women of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of childbearing potential"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Pregnant women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of any other serious medical condition (such as psychiatric illness, infectious diseases, physical or laboratory findings) that may interfere with the planned treatment, affect compliance or place the patient at high risk from treatment-related complications or potentially interfere with the completion of the treatment as per the protocol",
            "criterions": [
                {
                    "exact_snippets": "Evidence of any other serious medical condition (such as psychiatric illness, infectious diseases, physical or laboratory findings) that may interfere with the planned treatment, affect compliance or place the patient at high risk from treatment-related complications or potentially interfere with the completion of the treatment as per the protocol",
                    "criterion": "serious medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "potential to interfere with treatment or compliance or increase risk",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent",
            "criterions": [
                {
                    "exact_snippets": "Known allergy to any of the study medications",
                    "criterion": "allergy to study medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergy to ... their analogues",
                    "criterion": "allergy to analogues of study medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergy to ... excipients in the various formulations of any agent",
                    "criterion": "allergy to excipients in formulations of any agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver disease with Child-Pugh class B or C liver dysfunction",
            "criterions": [
                {
                    "exact_snippets": "Liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Child-Pugh class B or C liver dysfunction",
                    "criterion": "Child-Pugh class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current treatment with a combination of ibrutinib and strong CYP3A inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Current treatment with a combination of ibrutinib and strong CYP3A inhibitors",
                    "criterion": "current treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "combination therapy",
                            "expected_value": [
                                "ibrutinib",
                                "strong CYP3A inhibitors"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy =< 14 days prior to registration; if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy =< 14 days prior to registration",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib",
                    "criterion": "radiotherapy to small field",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days between treatment and administration of the ixazomib"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown",
            "criterions": [
                {
                    "exact_snippets": "this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown",
                    "criterion": "investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central nervous system involvement (Bing-Neel syndrome)",
            "criterions": [
                {
                    "exact_snippets": "Central nervous system involvement (Bing-Neel syndrome)",
                    "criterion": "central nervous system involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Bing-Neel syndrome",
                    "criterion": "Bing-Neel syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic anti-cancer therapy or participation in other clinical trials, including those with other investigational agents not included in this trial, =< 28 days of registration and throughout the duration of active treatment in this trial",
            "criterions": [
                {
                    "exact_snippets": "Systemic anti-cancer therapy ... =< 28 days of registration and throughout the duration of active treatment in this trial",
                    "criterion": "systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participation in other clinical trials, including those with other investigational agents not included in this trial, =< 28 days of registration and throughout the duration of active treatment in this trial",
                    "criterion": "participation in other clinical trials",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last participation",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Failure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior treatment for WM",
            "criterions": [
                {
                    "exact_snippets": "Failure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior treatment for WM",
                    "criterion": "recovery from reversible effects of prior treatment for WM",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has >= grade 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination during the screening period",
            "criterions": [
                {
                    "exact_snippets": "Patient has >= grade 2 peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 1 peripheral neuropathy with pain on clinical examination during the screening period",
                    "criterion": "peripheral neuropathy with pain",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "pain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the screening period"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of any other prior malignancy; (NOTE: Exception to this are adequately treated non-melanoma skin cancers, any in situ cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least two years prior to study enrollment)",
            "criterions": [
                {
                    "exact_snippets": "History of any other prior malignancy",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Exception ... adequately treated non-melanoma skin cancers",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Exception ... any in situ cancer",
                    "criterion": "in situ cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Exception ... adequately treated stage I or II cancer from which the patient is currently in complete remission",
                    "criterion": "stage I or II cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        },
                        {
                            "requirement_type": "remission status",
                            "expected_value": "complete remission"
                        }
                    ]
                },
                {
                    "exact_snippets": "Exception ... any other cancer from which the patient has been disease free for at least two years prior to study enrollment",
                    "criterion": "other cancer",
                    "requirements": [
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not; prior bortezomib treatment is allowed as per: patients with prior exposure to bortezomib will be allowed if they do not have disease refractory to bortezomib)",
            "criterions": [
                {
                    "exact_snippets": "Patients that have previously been treated with ixazomib",
                    "criterion": "prior ixazomib treatment",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participated in a study with ixazomib whether treated with ixazomib or not",
                    "criterion": "prior participation in ixazomib study",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior bortezomib treatment is allowed ... patients with prior exposure to bortezomib will be allowed if they do not have disease refractory to bortezomib",
                    "criterion": "disease refractory to bortezomib",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive",
            "criterions": [
                {
                    "exact_snippets": "Ongoing, active hepatitis B or C virus infection",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Ongoing, active hepatitis B or C virus infection",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known human immunodeficiency virus (HIV) positive",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "serostatus",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure (including open biopsy, excluding central line intravenous (IV) and port-a-cath placement) within =< 14 days prior to initiating study treatment, or anticipation of the need for major surgery during the course of the study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure (including open biopsy, excluding central line intravenous (IV) and port-a-cath placement) within =< 14 days prior to initiating study treatment",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "procedure type",
                            "expected_value": [
                                "major surgical procedure",
                                "open biopsy"
                            ]
                        },
                        {
                            "requirement_type": "procedure exclusion",
                            "expected_value": [
                                "central line intravenous (IV) placement",
                                "port-a-cath placement"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of the need for major surgery during the course of the study treatment",
                    "criterion": "anticipated need for major surgery",
                    "requirements": [
                        {
                            "requirement_type": "anticipated during study treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic treatment, =< 14 days before registration, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or St. John's wort",
            "criterions": [
                {
                    "exact_snippets": "Systemic treatment, =< 14 days before registration, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or St. John's wort",
                    "criterion": "systemic treatment with strong CYP3A inducers or St. John's wort",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "before registration"
                        },
                        {
                            "requirement_type": "drug_list",
                            "expected_value": [
                                "rifampin",
                                "rifapentine",
                                "rifabutin",
                                "carbamazepine",
                                "phenytoin",
                                "phenobarbital",
                                "St. John's wort"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ibrutinib, including difficulty swallowing",
            "criterions": [
                {
                    "exact_snippets": "Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ibrutinib",
                    "criterion": "gastrointestinal (GI) disease or GI procedure",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with oral absorption or tolerance of ixazomib or ibrutinib",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "difficulty swallowing",
                    "criterion": "difficulty swallowing",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Infection requiring systemic antibiotic therapy or other serious infection =< 7 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Infection requiring systemic antibiotic therapy",
                    "criterion": "infection requiring systemic antibiotic therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other serious infection =< 7 days prior to registration",
                    "criterion": "other serious infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, serious cardiac arrhythmia requiring medication (other than adequately rate-controlled atrial fibrillation), symptomatic congestive heart failure, unstable angina, stroke/transient ischemic attack (TIA) within the past 6 months or myocardial infarction within the past 6 months",
            "criterions": [
                {
                    "exact_snippets": "Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiac arrhythmia requiring medication (other than adequately rate-controlled atrial fibrillation)",
                    "criterion": "serious cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "medication requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "adequately rate-controlled atrial fibrillation"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke/transient ischemic attack (TIA) within the past 6 months",
                    "criterion": "stroke or transient ischemic attack (TIA)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the past 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Men or women of child bearing potential (WCBP) who are unwilling to employ effective contraception; effective contraception would be defined as utilizing 2 simultaneous methods of contraception from the time of signing consent through 90 days after the last dose of the study drugs unless they agree to participate in true abstinence when this is in line with the preferred and usual lifestyle of the subject; (WCBP: A female who is sexually mature and who: [1] has not undergone a hysterectomy or bilateral oophorectomy; or [2] has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time in the preceding 24 consecutive months])",
            "criterions": [
                {
                    "exact_snippets": "Men or women of child bearing potential (WCBP) who are unwilling to employ effective contraception; effective contraception would be defined as utilizing 2 simultaneous methods of contraception from the time of signing consent through 90 days after the last dose of the study drugs unless they agree to participate in true abstinence when this is in line with the preferred and usual lifestyle of the subject",
                    "criterion": "contraception use or abstinence",
                    "requirements": [
                        {
                            "requirement_type": "contraception or abstinence",
                            "expected_value": "must employ 2 simultaneous methods of contraception or agree to true abstinence from the time of signing consent through 90 days after the last dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of child bearing potential (WCBP): A female who is sexually mature and who: [1] has not undergone a hysterectomy or bilateral oophorectomy; or [2] has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time in the preceding 24 consecutive months]",
                    "criterion": "female reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "hysterectomy or bilateral oophorectomy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "postmenopausal status",
                            "expected_value": {
                                "operator": "<",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}